# Gemcitabine With/Out Capecitabine in Locally Advanced, Unresectable, or Metastatic Biliary Cancer

> **NCT00658593** · PHASE3 · TERMINATED · sponsor: **NCIC Clinical Trials Group** · enrollment: 19 (actual)

## Conditions studied

- Extrahepatic Bile Duct Cancer
- Gallbladder Cancer
- Liver Cancer

## Interventions

- **DRUG:** capecitabine
- **DRUG:** gemcitabine hydrochloride
- **PROCEDURE:** quality-of-life assessment

## Key facts

- **NCT ID:** NCT00658593
- **Lead sponsor:** NCIC Clinical Trials Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-10-10
- **Primary completion:** 2010-05-11
- **Final completion:** 2011-01-18
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** due to poor accrual
- **Last updated:** 2023-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00658593

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00658593, "Gemcitabine With/Out Capecitabine in Locally Advanced, Unresectable, or Metastatic Biliary Cancer". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT00658593. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*